Literature DB >> 2776391

Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects.

T Walle1, U K Walle, T D Cowart, E C Conradi.   

Abstract

This study determined the total clearance of propranolol and the partial clearances through each of its three primary metabolic pathways after administration of an 80 mg single oral dose in 28 young, white subjects (13 women; 15 men). The oral clearance of propranolol was significantly higher (63%, p less than 0.02) in the men (65.7 +/- 7.7 ml/min/kg; mean +/- SE) than in the women (40.2 +/- 6.2 ml/min/kg). This sex difference was mainly attributable to a 137% higher clearance through the P-450-mediated side-chain oxidation in the men (p less than 0.001). There was also a 52% higher clearance through glucuronidation in the men (p less than 0.02). In contrast, the clearance through the P-450-mediated ring oxidation was not different between men and women. After administration of simultaneous intravenous doses of hexadeuterium-labeled drug (0.1 mg/kg) to 11 of the subjects, there were no differences between men and women in volume of distribution or half-life. Moreover, there were no sex differences in plasma and blood binding of propranolol. This study thus demonstrates that higher plasma levels of propranolol occur in women than in men after oral doses and suggests that some drug metabolizing enzymes, but not others, are regulated by sex hormones in human beings.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776391     DOI: 10.1038/clpt.1989.136

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

Review 1.  Gender-specific differences in the central nervous system's response to anesthesia.

Authors:  Lana J Mawhinney; Davita Mabourakh; Michael C Lewis
Journal:  Transl Stroke Res       Date:  2012-11-29       Impact factor: 6.829

2.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Gender as a risk factor for adverse events to medications.

Authors:  J C Kando; K A Yonkers; J O Cole
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

4.  Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.

Authors:  K H Lew; E A Ludwig; M A Milad; K Donovan; E Middleton; J J Ferry; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1993-10       Impact factor: 6.875

Review 5.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 6.  Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.

Authors:  P Glue; R P Clement
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

7.  Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers.

Authors:  J Vanakoski; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

9.  The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers.

Authors:  U K Walle; T C Fagan; M J Topmiller; E C Conradi; T Walle
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 10.  Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.

Authors:  Kwame N Atuah; Dyfrig Hughes; Munir Pirmohamed
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.